{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:23:04Z","timestamp":1744086184478,"version":"3.40.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106350"],"award-info":[{"award-number":["JP19ck0106350"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Funds","award":["2023-J-03","29-A-3, 2020-J-3"],"award-info":[{"award-number":["2023-J-03","29-A-3, 2020-J-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The objective of this post-hoc analysis was to assess the inter-institutional heterogeneity in the overall survival and progression-free survival of patients with advanced biliary tract cancer treated with first-line chemotherapy in the JCOG1113 trial. The heterogeneity in the overall survival and progression-free survival was assessed according to three factors: hospital volume, experience in medical oncology and experience in biliary intervention. A total of 300 advanced biliary tract cancer patients were analyzed. There were no statistically significant trends observed between hospital volume, experience in medical oncology, or experience in biliary intervention and overall survival (hospital volume: adjusted trend P value\u00a0=\u00a00.6796; experience in medical oncology: adjusted trend P value\u00a0=\u00a00.4092; experience in biliary intervention: adjusted trend P value\u00a0=\u00a00.6112). Similarly, no statistically significant trends were observed between these factors and progression-free survival (hospital volume: adjusted trend P value\u00a0=\u00a00.3000; experience in medical oncology: adjusted trend P value\u00a0=\u00a00.1108; experience in biliary intervention: adjusted trend P value\u00a0=\u00a00.2898).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study revealed no inter-institutional heterogeneity in the overall survival and progression-free survival in the JCOG1113 study population of advanced biliary tract cancer patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae188","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T12:28:41Z","timestamp":1736339321000},"page":"355-361","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-0795","authenticated-orcid":false,"given":"Koh","family":"Fukushi","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , Kashiwa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-0095","authenticated-orcid":false,"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , Kashiwa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , Kashiwa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center, Clinical Research Support Office, National Cancer Center Hospital , Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-7503","authenticated-orcid":false,"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saitama Cancer Center , Saitama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-5217","authenticated-orcid":false,"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Cancer Center Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[{"name":"Department of Pancreatobiliary Surgery, Kansai Medical University , Hirakata ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, NHO Osaka National Hospital , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Chiba Cancer Center , Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-0101","authenticated-orcid":false,"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanazawa University Hospital , Kanazawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center , Yokohama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"JCOG Hepatobiliary and Pancreatic Oncology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Fukushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025040711072531300_ref1","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"2025040711072531300_ref2","doi-asserted-by":"publisher","first-page":"e3582","DOI":"10.1097\/MD.0000000000003582","article-title":"Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter","volume":"95","author":"Yamada","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025040711072531300_ref3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.6004\/jnccn.2019.7361","article-title":"Benefits of high-volume medical oncology Care for Noncurable Pancreatic Adenocarcinoma: a population-based analysis","volume":"18","author":"Hallet","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025040711072531300_ref4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"2025040711072531300_ref5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.gie.2020.12.035","article-title":"ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction","volume":"94","author":"Qumseya","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"2025040711072531300_ref6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.cgh.2017.06.002","article-title":"Association between endoscopist and center endoscopic retrograde cholangiopancreatography volume with procedure success and adverse outcomes: a systematic review and meta-analysis","volume":"15","author":"Keswani","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025040711072531300_ref7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.gie.2023.05.045","article-title":"Impact of center and endoscopist ERCP volume on ERCP outcomes: a systematic review and meta-analysis","volume":"98","author":"Teles de Campos","year":"2023","journal-title":"Gastrointest Endosc"},{"key":"2025040711072531300_ref8","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.eclinm.2019.11.005","article-title":"Higher volume providers are associated with improved outcomes following ERCP for the palliation of malignant biliary obstruction","volume":"3","author":"Harvey","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025040711072531300_ref9","doi-asserted-by":"publisher","first-page":"12835","DOI":"10.1007\/s00432-023-04966-x","article-title":"Hospital volume and prognosis of patients with metastatic pancreatic cancer: a study using the Osaka cancer registry","volume":"149","author":"Kawamoto","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025040711072531300_ref10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.lungcan.2018.06.025","article-title":"Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer","volume":"122","author":"Goyal","year":"2018","journal-title":"Lung Cancer"},{"key":"2025040711072531300_ref11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.surg.2020.05.023","article-title":"Are academic hospitals better at treating metastatic colorectal cancer?","volume":"169","author":"Atallah","year":"2021","journal-title":"Surgery"},{"key":"2025040711072531300_ref12","doi-asserted-by":"publisher","first-page":"e000031","DOI":"10.1136\/esmoopen-2015-000031","article-title":"Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial","volume":"1","author":"Kurokawa","year":"2016","journal-title":"ESMO Open"},{"key":"2025040711072531300_ref13","article-title":"Clinical practice guidelines in oncology: biliary tract cancers","author":"Network","year":"2023","journal-title":"Version 32023"},{"key":"2025040711072531300_ref14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025040711072531300_ref15","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2025040711072531300_ref16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2025040711072531300_ref17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2025040711072531300_ref18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025040711072531300_ref19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025040711072531300_ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_320041","article-title":"Supportive care: low cost, high value","volume":"41","author":"Popescu","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/355\/61373497\/hyae188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/355\/61373497\/hyae188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:01:05Z","timestamp":1744038065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/4\/355\/7945397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,8]]},"published-print":{"date-parts":[[2025,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae188","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,8]]}}}